Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2
Top Cited Papers
Open Access
- 16 June 2020
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 94 (13)
- https://doi.org/10.1128/jvi.00510-20
Abstract
Genetic variability across the three major histocompatibility complex (MHC) class I genes (human leukocyte antigen A [HLA-A], -B, and -C genes) may affect susceptibility to and severity of the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). We performed a comprehensive in silico analysis of viral peptide-MHC class I binding affinity across 145 HLA-A, -B, and -C genotypes for all SARS-CoV-2 peptides. We further explored the potential for cross-protective immunity conferred by prior exposure to four common human coronaviruses. The SARS-CoV-2 proteome was successfully sampled and was represented by a diversity of HLA alleles. However, we found that HLA-B*46:01 had the fewest predicted binding peptides for SARS-CoV-2, suggesting that individuals with this allele may be particularly vulnerable to COVID-19, as they were previously shown to be for SARS (M. Lin, H.-T. Tseng, J. A. Trejaut, H.-L. Lee, et al., BMC Med Genet 4:9, 2003, https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-4-9). Conversely, we found that HLA-B*15:03 showed the greatest capacity to present highly conserved SARS-CoV-2 peptides that are shared among common human coronaviruses, suggesting that it could enable cross-protective T-cell-based immunity. Finally, we reported global distributions of HLA types with potential epidemiological ramifications in the setting of the current pandemic. IMPORTANCE Individual genetic variation may help to explain different immune responses to a virus across a population. In particular, understanding how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease. HLA typing can be fast and inexpensive. Pairing HLA typing with COVID-19 testing where feasible could improve assessment of severity of viral disease in the population. Following the development of a vaccine against SARS-CoV-2, the virus that causes COVID-19, individuals with high-risk HLA types could be prioritized for vaccination.Keywords
Funding Information
- Sunlin & Priscilla Chou Foundation
- U.S. Department of Veterans Affairs (1IK2CX002049-01)
This publication has 90 references indexed in Scilit:
- Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8 + T cellsProceedings of the National Academy of Sciences of the United States of America, 2013
- Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in PsoriasisPLOS ONE, 2012
- Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine stormsNature Reviews Immunology, 2011
- Definition of epitopes and antigens recognized by vaccinia specific immune responses: Their conservation in variola virus sequences, and use as a model system to study complex pathogensVaccine, 2009
- Complete but curtailed T-cell response to very low-affinity antigenNature, 2009
- Jalview Version 2—a multiple sequence alignment editor and analysis workbenchBioinformatics, 2009
- Severe Acute Respiratory Syndrome Coronavirus Pathogenesis, Disease and VaccinesThe Pediatric Infectious Disease Journal, 2004
- Probable Secondary Infections in Households of SARS Patients in Hong KongEmerging Infectious Diseases, 2004
- HLA‐A and ‐B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic ThaisTissue Antigens, 2002
- Influence of HLA Supertypes on Susceptibility and Resistance to Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 2000